Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome with and without Hunner Lesion: A Review and Future Perspectives
- PMID: 34943475
- PMCID: PMC8700457
- DOI: 10.3390/diagnostics11122238
Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome with and without Hunner Lesion: A Review and Future Perspectives
Abstract
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating urinary bladder condition that presents with a wide variety of clinical phenotypes. It is commonly characterized by persistent pelvic pain and lower urinary tract symptoms, such as urinary frequency and urgency. Current clinicopathological and genomic evidence has indicated that IC/BPS with Hunner lesions is a clinically relevant distinct subtype with proven bladder pathology of subepithelial chronic inflammatory changes that are characterized by enhanced local immune responses and epithelial denudation. However, other forms of IC/BPS lacking Hunner lesions are a symptom syndrome complex of non-inflammatory conditions with little evidence of bladder etiology, characterized by aberrant neural activity in neurotransmission systems which leads to central nervous sensitization with potential involvement of urothelial malfunction, or clinical presentation of somatic and/or psychological symptoms beyond the bladder. Given such distinct potential pathophysiology between IC/BPS subtypes, disease biomarkers of IC/BPS should be provided separately for subtypes with and without Hunner lesions. Tailored approaches that target characteristic immunological inflammatory processes and epithelial denudation for IC/BPS with Hunner lesions, or the sensitized/altered nervous system, urothelial malfunction, association with other functional somatic syndromes, and psychosocial problems for IC/BPS without Hunner lesions, are essential to identify optimal and reliable disease-specific IC/BPS biomarkers.
Keywords: IC/BPS; PBS; biomarker; bladder pain syndrome; interstitial cystitis.
Conflict of interest statement
The author has no relevant financial interests to disclose.
Similar articles
-
Interstitial cystitis/bladder pain syndrome: The evolving landscape, animal models and future perspectives.Int J Urol. 2020 Jun;27(6):491-503. doi: 10.1111/iju.14229. Epub 2020 Apr 4. Int J Urol. 2020. PMID: 32246572 Free PMC article. Review.
-
Pathology and terminology of interstitial cystitis/bladder pain syndrome: A review.Histol Histopathol. 2019 Jan;34(1):25-32. doi: 10.14670/HH-18-028. Epub 2018 Jul 17. Histol Histopathol. 2019. PMID: 30015351 Review.
-
Current Understanding and Future Perspectives of Interstitial Cystitis/Bladder Pain Syndrome.Int Neurourol J. 2021 Jun;25(2):99-110. doi: 10.5213/inj.2142084.042. Epub 2021 Jun 30. Int Neurourol J. 2021. PMID: 34218637 Free PMC article.
-
Phenotyping of interstitial cystitis/bladder pain syndrome.Int J Urol. 2019 Jun;26 Suppl 1:17-19. doi: 10.1111/iju.13969. Int J Urol. 2019. PMID: 31144756 Review.
-
Urinary Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome and Its Impact on Therapeutic Outcome.Diagnostics (Basel). 2021 Dec 29;12(1):75. doi: 10.3390/diagnostics12010075. Diagnostics (Basel). 2021. PMID: 35054241 Free PMC article. Review.
Cited by
-
Dietary Influence on Bladder Pain Syndrome: A Systematic Review.Cureus. 2024 Sep 15;16(9):e69437. doi: 10.7759/cureus.69437. eCollection 2024 Sep. Cureus. 2024. PMID: 39411625 Free PMC article. Review.
-
Therapeutic Approaches for Urologic Chronic Pelvic Pain Syndrome; Management: Research Advances, Experimental Targets, and Future Directions.J Pharmacol Exp Ther. 2024 Jul 18;390(2):222-232. doi: 10.1124/jpet.123.002081. J Pharmacol Exp Ther. 2024. PMID: 38565309 Review.
-
Combination of urinary biomarkers and machine-learning models provided a higher predictive accuracy to predict long-term treatment outcomes of patients with interstitial cystitis/bladder pain syndrome.World J Urol. 2024 Mar 20;42(1):173. doi: 10.1007/s00345-024-04843-3. World J Urol. 2024. PMID: 38507059
-
Bioenergetic profiles of peripheral mononuclear cells and systemic inflammation in women with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS).PLoS One. 2024 Feb 15;19(2):e0298981. doi: 10.1371/journal.pone.0298981. eCollection 2024. PLoS One. 2024. PMID: 38359038 Free PMC article.
-
TRPV4 activation prevents lipopolysaccharide-induced painful bladder hypersensitivity in rats by regulating immune pathways.Front Immunol. 2022 Dec 22;13:1080302. doi: 10.3389/fimmu.2022.1080302. eCollection 2022. Front Immunol. 2022. PMID: 36618411 Free PMC article.
References
-
- Van de Merwe J.P., Nordling J., Bouchelouche P., Bouchelouche K., Cervigni M., Daha L.K., Elneil S., Fall M., Hohlbrugger G., Irwin P., et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: An ESSIC proposal. Eur. Urol. 2008;53:60–67. doi: 10.1016/j.eururo.2007.09.019. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources